Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.82 USD | -0.23% | -1.99% | +18.56% |
May. 22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.56% | 5.58B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Berenberg Bank Adjusts Halozyme Therapeutics' Price Target to $56 From $58, Maintains Buy Rating